Siegfried Holding (SFZN.SW) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

SFZN.SW · Stock Price

CHF 83.35-14.25 (-14.60%)

Market Cap: $4.7B

Historical price data

Market Cap: $4.7BFounded: 1873Employees: 3,000-4,000HQ: Zofingen, Switzerland

Overview

Siegfried is a mission-critical Swiss CDMO that partners with pharmaceutical and biotech companies to develop and manufacture their drug substances and products at scale. Its strategy is built on deep technical expertise in complex chemistry, a fully integrated global network, and a resilient business model serving the essential needs of the pharma supply chain. The company has demonstrated consistent profitable growth, supported by strategic acquisitions like the planned US drug substance capacity expansion announced in January 2026, and maintains a strong financial position evidenced by successful bond placements.

Biotech

Technology Platform

An integrated CDMO platform spanning active pharmaceutical ingredient (API) development and manufacturing through finished dosage form (FDF) production, with specialized expertise in complex chemical synthesis, highly potent APIs (HPAPIs), controlled substances, and viral vectors.

Opportunities

Siegfried is poised to capitalize on the strong secular trend of pharmaceutical outsourcing, particularly for complex molecules like HPAPIs and controlled substances.

Its expansion into viral vector manufacturing and strategic acquisition of US-based API capacity position it in high-growth niches of the CDMO market.

Risk Factors

Key risks include operational execution at new and acquired sites, potential pricing pressure from increased CDMO competition, and dependency on the clinical and commercial success of its clients' drug pipelines.

Regulatory compliance across its global network remains a constant vigilance point.

Competitive Landscape

Siegfried competes with large, global CDMOs like Lonza and Catalent, as well as niche API specialists. Its competitive advantages are its fully integrated API-to-FDF model, deep technical expertise in complex chemistry, and the strong reputation of its Swiss quality and regulatory heritage.

More companies in Switzerland →